News & Updates

In the treatment of patients with pulmonary hypertension (PH) with fibrotic interstitial lung disease (ILD), a higher dose of inhaled treprostinil or getting at least nine breaths four times daily increases the likelihood of achieving clinical improvement and preventing clinical worsening, according to a study.

Early, long-term lipid lowering with the PCSK9 inhibitor evolocumab further reduces cardiovascular (CV) events, including CV death, without any safety signal, in the FOURIER* open-label extension (OLE) study.

Dual HER-2 inhibition with tucatinib and trastuzumab induces clinically meaningful and durable responses in patients with previously treated metastatic HER2-positive colorectal cancer (mCRC) in the phase II MOUNTAINEER trial, boosting hopes for this chemotherapy-free combination.

Implementing a clinical pharmacist-led service program has led to the standardization and streamlining of refractory chemotherapy-induced nausea and vomiting (CINV) management in adult haematology and oncology clinics, reports a study.

The administration of intravenous vitamin C to patients with sepsis admitted to the intensive care unit (ICU) did not result in a reduced risk of death or organ dysfunction, according to results of the phase III LOVIT* trial.

Early rhythm control (ERC) appears to cut the risk of adverse cardiovascular outcomes in atrial fibrillation (AF) patients with a CHA2DS2-VASc score of ≥4, a study has found.

The real-world effectiveness of eribulin in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer is lower than that seen in clinical trials, reveals a study.